Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962

Benzinga Newsdesk www.benzinga.com Negative 88.7%

Neg 88.7% Neu 0% Pos 0%

Barclays analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and lowers the price target from $964 to $962.